Stay updated with breaking news from Abivax. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
28.04.2022 - DGAP-News: ABIVAX / Key word(s): Annual Report Abivax publishes Universal Registration Document 2022 'Document d'Enregistrement Universel' 28.04.2022 / 18:00 The issuer is solely responsible for the content of this announcement. Abivax publishes ... Seite 1
PARIS, FRANCE / ACCESSWIRE / April 28, 2022 / Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat
Feedback received from the US and European regulatory agencies, both supporting the advancement ABX464 into a phase 3 clinical program in ulcerative colitis (UC), final preparations for the launch of the
Abivax SA , a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today announces its... | March 16, 2022
Treatment demonstrated a good safety profile in the overall patient population during the 12-week induction phase - News - PharmaTimes